These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 26842489

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ, Alzahrani N, Alzahrani S, Traiki TB, Liauw W, Morris DL.
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [Abstract] [Full Text] [Related]

  • 3. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM, Kwong TG, Ma GL, Messer K, Kelly KJ, Lowy AM.
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
    Dreznik Y, Hoffman A, Hamburger T, Ben-Yaacov A, Dux Y, Jacoby H, Berger Y, Nissan A, Gutman M.
    Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
    [Abstract] [Full Text] [Related]

  • 7. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F, Thievenaz R, Decullier E, Bakrin N, Cotte E, Rousset P, Vaudoyer D, Passot G, Glehen O.
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM.
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [Abstract] [Full Text] [Related]

  • 11. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR, Braam HJ, Luyer MD, Wiezer MJ, van Ramshorst B, Nienhuijs SW, de Hingh IH.
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [Abstract] [Full Text] [Related]

  • 12. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
    Malfroy S, Wallet F, Maucort-Boulch D, Chardonnal L, Sens N, Friggeri A, Passot G, Glehen O, Piriou V.
    Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
    [Abstract] [Full Text] [Related]

  • 13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT, Yang XJ, Huang CQ, Sun JH, Ji ZH, Peng KW, Zhang Q, Li Y.
    World J Surg Oncol; 2016 Sep 15; 14(1):246. PubMed ID: 27633880
    [Abstract] [Full Text] [Related]

  • 14. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
    Simkens GA, van Oudheusden TR, Braam HJ, Luyer MD, Wiezer MJ, van Ramshorst B, Nienhuijs SW, de Hingh IH.
    Ann Surg Oncol; 2016 Jan 15; 23(1):99-105. PubMed ID: 26148758
    [Abstract] [Full Text] [Related]

  • 15. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
    Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quénet F, Eveno C, Pocard M, Goere D, Elias D, Ortega-Deballon P, Vaudoyer D, Cotte E, Glehen O.
    Ann Surg Oncol; 2016 Jul 15; 23(7):2315-22. PubMed ID: 26920385
    [Abstract] [Full Text] [Related]

  • 16. Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Kelly KJ, Cajas L, Baumgartner JM, Lowy AM.
    Ann Surg Oncol; 2018 Jan 15; 25(1):91-97. PubMed ID: 29090402
    [Abstract] [Full Text] [Related]

  • 17. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X, Li Z, Li Z, Jia Y, Shan F, Ji X, Bu Z, Zhang L, Wu A, Ji J.
    J Surg Oncol; 2015 Jun 15; 111(7):840-7. PubMed ID: 25864884
    [Abstract] [Full Text] [Related]

  • 18. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC, Chia CS, Tan SH, Soo KC, Teo MCC.
    Int J Clin Oncol; 2018 Oct 15; 23(5):989-998. PubMed ID: 29869757
    [Abstract] [Full Text] [Related]

  • 19. Morbidity of the abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
    Nunez MF, Sardi A, Nieroda C, Jimenez W, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V.
    Ann Surg Oncol; 2015 May 15; 22(5):1658-63. PubMed ID: 25245127
    [Abstract] [Full Text] [Related]

  • 20. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
    Ye J, Ren Y, Wei Z, Peng J, Chen C, Song W, Tan M, He Y, Yuan Y.
    Surg Oncol; 2018 Sep 15; 27(3):456-461. PubMed ID: 30217302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.